AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions (NCT06959524)
AGENT DCB STANCE: AGENT Drug-Coated Balloon for STent AvoidANCE in PCI for De Novo Coronary Artery Disease
🩺 Plain-English Summary (8th-Grade Level)
AGENT DCB STANCE is a prospective, multicenter, open-label, 1:1 randomized controlled study designed to assess the safety and effectiveness of a treatment strategy with the AGENT Drug-Coated Balloon compared to standard of care percutaneous coronary intervention (PCI) treatment with drug eluting stent (DES) and/or balloon angioplasty in patients with de novo coronary lesions. Subjects must have a de novo target lesion located in a native coronary artery.
Who can join: Review the eligibility criteria below.
Location: St. Bernard's Medical Center — Jonesboro, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (68 Sites)
Showing the first 25 of 68 sites.
- St. Bernard's Medical Center — Jonesboro, Arkansas
- Scripps Memorial Hospital — La Jolla, California
- USC Medical Center — Los Angeles, California
- Cedars - Sinai Medical Center — Los Angeles, California
- University of California San Francisco — San Francisco, California
- Stanford University Medical Center — Stanford, California
- Los Robles Hospital & Medical Center — Thousand Oaks, California
- South Denver Cardiology Associates, PC — Littleton, Colorado
- The Cardiac and Vascular Institute Research Foundation — Gainesville, Florida
- Mount Sinai Medical Center — Miami Beach, Florida
- Piedmont Hospital — Atlanta, Georgia
- Emory University Hospital — Atlanta, Georgia
- Wellstar Kennestone Hospital — Marietta, Georgia
- Northwestern University — Evanston, Illinois
- Endeavor Health — Glenview, Illinois
- Massachusetts General Hospital — Boston, Massachusetts
- Brigham and Women's Hospital — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- University of Michigan Hospitals — Ann Arbor, Michigan
- Henry Ford Hospital — Detroit, Michigan
- Corewell Health — Grand Rapids, Michigan
- Mercy Hospital — Coon Rapids, Minnesota
- St. Luke's Hospital of Kansas City — Kansas City, Missouri
- NYU Langone Hospital — Brooklyn, New York
- Mount Sinai Medical Center — New York, New York
📞 Contact the Study Coordinator
Phone: (508) 683-6560
Email: beth.lawson@bsci.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Coronary Arterial Disease (CAD)
- Colonoscopy and Antiplatelet Therapy Trial — New Orleans, Louisiana
- The Switching Antiplatelet-9 (SWAP-9) Study — Jacksonville, Florida
- The Bridging Antiplatelet Therapy With Cangrelor 2 Study — Jacksonville, Florida
- Restrospective Analysis of MACE in Patients Treated With Drug-elluting Balloons. — Québec, Quebec
- FORWARD CAD IDE Study — La Jolla, California
Explore by condition: All Coronary Arterial Disease (CAD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.